Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial
June 23 (Reuters) - Compass Pathways PLC CMPS.O:
COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION
COMPASS PATHWAYS PLC - COMP360 SHOWS SIGNIFICANT REDUCTION IN SYMPTOM SEVERITY IN PHASE 3 TRIAL
COMPASS PATHWAYS PLC - DSMB FINDS NO UNEXPECTED SAFETY ISSUES WITH COMP360
COMPASS PATHWAYS PLC - COMP006 TRIAL 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

Nvidia Shares Hit Record High, Market Cap Tops $526 Trillion, How Much Higher Can It Go Amid AI Capex Boom?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Tradingkey








